[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eye Research Associates, LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100658254","phase-4-contact-lens-wearing-dry-eye-subjects-who-are-treated-with-acoltremon-0003-100658254",false,"NCT07848373","Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%","A Clinical Evaluation of Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%","Inclusion Criteria:\n\n* • Adult subjects who are ≥18 years of age.\n\n  * Best corrected CL visual acuity of 0.1 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20\u002F25).\n  * Willing to wear a new pair of CLs to the baseline study visit.\n  * Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs).\n  * An Eye Dryness VAS score of ≥40.\n  * CLDEQ-8 scores (CLDEQ-8 scores ≥12).\n  * A score of \\>7 dots on the Lexitas NEI staining scale (grade 1 in a single sector on the 5-sector scale).\n  * Habitual wearers of soft CLs for a minimum of 5 days per week for 6 hours or more per day during the month prior to enrollment.\n  * Willing to maintain habitual soft CL wear of a minimum of 5 days per week for 6 or more hours per day for the 1 month duration of the study.\n  * Habitual CLs have an acceptable fit (good centration, movement, and coverage\n\nExclusion Criteria:\n\n* Any history of acoltremon 0.003% use.\n* Are currently an overnight CL wearer.\n* Are currently hard or scleral CL wearers.\n* Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).\n* Have a history of ocular surgery within the past 12 months.\n* Have a history of viral eye disease that may confound study results.\n* Have a history of severe ocular trauma, active ocular infection or inflammation.\n* Have ever used isotretinoin-derivates (e.g., Accutane).\n* Are currently taking ocular medications (including topical glaucoma medication) or plan to during the study.\n* Have had a physical meibomian gland treatment withing 1 month of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.).\n* Have used a prescription DED medication in the last 1 month.\n* Unwilling to agree to discontinue artificial tear use the day before enrollment and throughout the study.\n* Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation.\n* Are pregnant or breast feeding.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.",[26,27,28],"Dry Eye","Contact Lens Discomfort","Eye Drops","NOT_YET_RECRUITING","2026-10-06",{"date":32,"type":33},"2026-10-08","ACTUAL",{"date":35,"type":20},"2026-10-10",{"date":37,"type":20},"2027-02-21",{"name":39,"class":40},"Eye Research Associates, LLC","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100654285","phase-4-evaluation-of-lacrifill-100654285","NCT07796178","Evaluation of Lacrifill","Evaluation of Lacrifill Treatment for Alleviating Dry Eye Symptoms in Post-Operative Cataract Surgery Subjects","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Have the potential of 20\u002F40 visual acuity or better post-cataract surgery.\n* have cataract surgery scheduled for both eyes\n* Corneal staining score of ≥3 on the original National Eye Institute (NEI; 0-15 total score) staining scale in the study eye.\n* willing to discontinue contact lens throughout the study?\n* pre-treatment OSDI scores of ≤12 (asymptomatic)?\n\nExclusion Criteria:\n\n* Known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome)?\n* History of ocular surgery within the past 12 months (excluding cataract surgery)\n* Anticipated complications from cataract surgery in either eye?\n* History of severe ocular trauma, active ocular infection or inflammation that is not dry eye-related?\n* Used Accutane or is currently using ocular medications\u002Ftreatments outside of study treatments? Artificial tears will be allowed.\n* Physical meibomian gland treatment withing 1 month of enrollment?\n* Having any conditions or are in a situation, which in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study.\n* Currently pregnant or breast feeding","80 Years",{"count":50,"type":20},40,[23],"Dry Eye Disease is defined as \"a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.' 'By the The Tear Film and Ocular Surface Society. Despite there being a number of factors that impact DED however one factor that has been considered likely is that of a complication from ocular surgery itself. Which can cause both corneal nerve, and ocular surface damage. Therefore this study aims to determine how Lacrfill performs in preventing post-operative dry eye symptoms in those who have recently had unilateral cataract surgery.",[26,54,55,56],"Ocular Surface Disease","Cataract Surgery","Eyes Dry Feeling of","RECRUITING","2026-09-22",{"date":60,"type":33},"2026-09-25",{"date":62,"type":33},"2026-09-02",{"date":64,"type":20},"2027-02-15",{"name":39,"class":40},""]